Similar articles

• Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.

  Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R. Andoh T, et al. Oncol Res. 1996;8(6):229-38. Oncol Res. 1996. PMID: 8895198
• Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.

  Jain N, Lam YM, Pym J, Campling BG. Jain N, et al. Cancer. 1996 May 1;77(9):1797-808. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1797::AID-CNCR7>3.0.CO;2-9. Cancer. 1996. PMID: 8646677
• Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

  Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH. Rothenborg-Jensen L, et al. Anticancer Drug Des. 2001 Dec;16(6):305-15. Anticancer Drug Des. 2001. PMID: 12375883
• Evidence for multidrug-resistant cells in human tumor cell populations.

  Shoemaker RH, Curt GA, Carney DN. Shoemaker RH, et al. Cancer Treat Rep. 1983 Oct;67(10):883-8. Cancer Treat Rep. 1983. PMID: 6313186 Review.
• New drugs for the management of lung cancer.

  Giaccone G. Giaccone G. Br J Hosp Med. 1996 May 15-Jun 4;55(10):634-8. Br J Hosp Med. 1996. PMID: 8762124 Review. No abstract available.